Top

Cancer Immunology, Immunotherapy

Published in:

01-11-2009 | Original article

Onconeural antibodies in sera from patients with various types of tumours

Authors: Sissel Evy Monstad, Anette Knudsen, Helga B. Salvesen, Jan H. Aarseth, Christian A. Vedeler

Published in: Cancer Immunology, Immunotherapy | Issue 11/2009

Abstract

Purpose

We assessed the frequency and levels of onconeural antibodies in 974 patients with various types of tumours, but without apparent paraneoplastic neurological syndromes (PNS).

Patients and methods

We included patients with the following tumours: 200 small-cell lung cancer (SCLC) patients, 253 breast cancer patients, 182 ovarian cancer patients, 266 uterine cancer patients and 73 thymoma patients, as well as 52 patients with PNS and cancer and 300 healthy blood donors. Sera were screened for amphiphysin, CRMP5, Hu, Ma2, Ri and Yo antibodies using a multi-well immunoprecipitation technique.

Results

The most frequently detected antibodies were Hu followed by CRMP5. Ma2, Yo, amphiphysin and Ri antibodies were less common, but each was found at similar frequencies. Onconeural antibodies were present at similar levels in sera from the PNS control group and from cancer patients. Hu antibodies were rare in cancers other than SCLC. CRMP5 was the only antibody found in patients with thymoma and this antibody was more common among patients with thymoma than in other tumour patients. With one exception, coexisting antibodies were only found in patients with SCLC. The presence of onconeural antibodies in SCLC patients was not associated with prolonged survival.

Conclusion

Onconeural antibodies are associated with various types of tumours suggesting that all antibodies should be included in the serological screening for possible PNS. The levels of onconeural antibody are not sufficiently sensitive to discriminate between cancer patients with PNS and those without.

Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15:2866–2872PubMed

Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka-Setinek U, Marzorati L, Wondrusch E, Cavaletti G (1997) Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 244:85–89PubMedCrossRef

Pittock SJ, Kryzer TJ, Lennon VA (2004) Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56:715–719PubMedCrossRef

Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795–800PubMedCrossRef

Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53–58PubMedCrossRef

Knudsen A, Monstad SE, Dorum A, Lonning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006) Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 55:1280–1284PubMedCrossRef

Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA (2008) CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother 57:227–232PubMedCrossRef

Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140PubMedCrossRef

Husebye ES, Gebre-Medhin G, Tuomi T, Perheentupa J, Landin-Olsson M, Gustafsson J, Rorsman F, Kampe O (1997) Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 82:147–150PubMedCrossRef

10.

Falorni A, Ortqvist E, Persson B, Lernmark A (1995) Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 186:89–99PubMedCrossRef

11.

Falorni A, Nikoshkov A, Laureti S, Grenback E, Hulting AL, Casucci G, Santeusanio F, Brunetti P, Luthman H, Lernmark A (1995) High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 80:2752–2755PubMedCrossRef

12.

Ekwall O, Hedstrand H, Grimelius L, Haavik J, Perheentupa J, Gustafsson J, Husebye E, Kampe O, Rorsman F (1998) Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 352:279–283PubMedCrossRef

13.

Bradwell AR (2000) Paraneoplastic neurological syndromes associated with Yo, Hu, and Ri autoantibodies. Clin Rev Allergy Immunol 19:19–29PubMedCrossRef

14.

Benyahia B, Amoura Z, Rousseau A, Le Clanche C, Carpentier A, Piette JC, Delattre JY (2003) Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases. J Neurooncol 62:349–351PubMedCrossRef

15.

Vernino S, Lennon VA (2004) Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 10:7270–7275PubMedCrossRef

16.

Graus F, Cordon-Cardo C, Posner JB (1985) Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 35:538–543PubMed

17.

Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154PubMedCrossRef

18.

Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62:778–782PubMed

19.

Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, Butler M, De Camilli P, Michel D (1999) Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 56:172–177PubMedCrossRef

20.

Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kim KK, Kilimann MW, Lennon VA (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107PubMedCrossRef

21.

Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, Graus F (1999) Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 66:214–217PubMedCrossRef

22.

Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937PubMed

23.

Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53:580–587PubMedCrossRef

24.

Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, Dalmau J (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340:1788–1795PubMedCrossRef

Title: Onconeural antibodies in sera from patients with various types of tumours
Authors: Sissel Evy Monstad
Anette Knudsen
Helga B. Salvesen
Jan H. Aarseth
Christian A. Vedeler
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0690-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2009

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients

Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli

Selected allogeneic dendritic cells markedly enhance human tumour antigen-specific T cell response in vitro

Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene

Keynote webinar | Spotlight on antibody–drug conjugates in cancer